Մասնակից:Giragos16/Սեւագրութիւն

Duchenne muscular dystrophy (DMD) is a severe type of muscular dystrophy.[1] The symptom of muscle weakness usually begins around the age of four in boys and worsens quickly.[2] Typically muscle loss occurs first in the thighs and pelvis followed by those of the arms.[1] This can result in trouble standing up.[1] Most are unable to walk by the age of 12.[2] Affected muscles may look larger due to increased fat content.[1] Scoliosis is also common.[1] Some may have intellectual disability.[1] Females with a single copy of the defective gene may show mild symptoms.[1]

The disorder is X-linked recessive.[1] About two thirds of cases are inherited from a person's mother, while one third of cases are due to a new mutation.[1] It is caused by a mutation in the gene for the protein dystrophin.[1] Dystrophin is important to maintain the muscle fiber's cell membrane.[1] Genetic testing can often make the diagnosis at birth.[1] Those affected also have a high level of creatine kinase in their blood.[1]

Although there is no known cure, physical therapy, braces, and corrective surgery may help with some symptoms.[2] Assisted ventilation may be required in those with weakness of breathing muscles.[1] Medications used include steroids to slow muscle degeneration, anticonvulsants to control seizures and some muscle activity, and immunosuppressants to delay damage to dying muscle cells.[2]

DMD affects about one in 5,000 males at birth.[1] It is the most common type of muscular dystrophy.[1] The average life expectancy is 26;[3] however, with excellent care, some may live into their 30s or 40s.[1] Gene therapy, as a treatment, is in the early stages of study in humans.[1]

Signs and symptoms[Խմբագրել | Խմբագրել աղբիւրը]

Կաղապար:More medical citations needed The main symptom of DMD, a progressive neuromuscular disorder, is muscle weakness associated with muscle wasting with the voluntary muscles[աղբիւրի կարիք ունի] being first affected, especially those of the hips, pelvic area, thighs, shoulders, and calves. Muscle weakness also occurs later, in the arms, neck, and other areas. Calves are often enlarged. Symptoms usually appear before age six and may appear in early infancy. Other physical symptoms are:

Կաղապար:Columns-list

According to Lewis P. Rowland, in the anthology Gene Expression In Muscle, if a boy is affected with DMD, the condition can be observed clinically from the moment he takes his first steps. It becomes harder and harder for the boy to walk; his ability to walk usually completely disintegrates between the time the boy is 9 to 12 years of age. Most men affected with DMD become essentially “paralyzed from the neck down” by the age of 21.[4] Muscle wasting begins in the legs and pelvis, then progresses to the muscles of the shoulders and neck, followed by loss of arm muscles and respiratory muscles. Calf muscle enlargement (pseudohypertrophy) is quite obvious. Cardiomyopathy particularly (dilated cardiomyopathy) is common, but the development of congestive heart failure or arrhythmia (irregular heartbeat) is only occasional. Կաղապար:Columns-list

Cause[Խմբագրել | Խմբագրել աղբիւրը]

DMD is inherited in a X-linked recessive manner

DMD is caused by a mutation of the dystrophin gene at locus Xp21, located on the short arm of the X chromosome.[5] Dystrophin is responsible for connecting the cytoskeleton of each muscle fiber to the underlying basal lamina (extracellular matrix), through a protein complex containing many subunits. The absence of dystrophin permits excess calcium to penetrate the sarcolemma (the cell membrane).[6] Alterations in calcium and signalling pathways cause water to enter into the mitochondria, which then burst.

In skeletal muscle dystrophy, mitochondrial dysfunction gives rise to an amplification of stress-induced cytosolic calcium signals and an amplification of stress-induced reactive-oxygen species production. In a complex cascading process that involves several pathways and is not clearly understood, increased oxidative stress within the cell damages the sarcolemma and eventually results in the death of the cell. Muscle fibers undergo necrosis and are ultimately replaced with adipose and connective tissue.[աղբիւրի կարիք ունի]

DMD is inherited in an X-linked recessive pattern. Females typically are carriers of the genetic trait while males are affected. A female carrier will be unaware she carries a mutation until she has an affected son. The son of a carrier mother has a 50% chance of inheriting the defective gene from his mother. The daughter of a carrier mother has a 50% chance of being a carrier and a 50% chance of having two normal copies of the gene. In all cases, an unaffected father either passes a normal Y to his son or a normal X to his daughter. Female carriers of an X-linked recessive condition, such as DMD, can show symptoms depending on their pattern of X-inactivation.[աղբիւրի կարիք ունի] DMD has an incidence of one in 3,600 male infants.[7] Mutations within the dystrophin gene can either be inherited or occur spontaneously during germline transmission.[աղբիւրի կարիք ունի]

DMD is extremely rare in females (about 1 in 50,000,000 female births).[8] It can occur in females with an affected father and a carrier mother, in those who are missing an X chromosome, or those who have an inactivated X chromosome (the most common of the rare reasons).[9] The daughter of a carrier mother and an affected father will be affected or a carrier with equal probability, as she will always inherit the affected X-chromosome from her father and has a 50% chance of also inheriting the affected X-chromosome from her mother.[10]

Disruption of the blood-brain barrier has been seen to be a noted feature in the development of DMD.[11]

Diagnosis[Խմբագրել | Խմբագրել աղբիւրը]

Genetic counseling is advised for people with a family history of the disorder. DMD can be detected with about 95% accuracy by genetic studies performed during pregnancy.[7]

DNA test[Խմբագրել | Խմբագրել աղբիւրը]

The muscle-specific isoform of the dystrophin gene is composed of 79 exons, and DNA testing and analysis can usually identify the specific type of mutation of the exon or exons that are affected. DNA testing confirms the diagnosis in most cases.[12]

Muscle biopsy[Խմբագրել | Խմբագրել աղբիւրը]

If DNA testing fails to find the mutation, a muscle biopsy test may be performed.[13] A small sample of muscle tissue is extracted using a biopsy needle. The key tests performed on the biopsy sample for DMD are immunocytochemistry and immunoblotting for dystrophin, and should be interpreted by an experienced neuromuscular pathologist.[14] These tests provide information on the presence or absence of the protein. Absence of the protein is a positive test for DMD. Where dystrophin is present, the tests indicate the amount and molecular size of dystrophin, helping to distinguish DMD from milder dystrophinopathy phenotypes.[15] Over the past several years, DNA tests have been developed that detect more of the many mutations that cause the condition, and muscle biopsy is not required as often to confirm the presence of DMD.[16]

Prenatal tests[Խմբագրել | Խմբագրել աղբիւրը]

DMD is carried by an X-linked recessive gene. Males have only one X chromosome, so one copy of the mutated gene will cause DMD. Fathers cannot pass X-linked traits on to their sons, so the mutation is transmitted by the mother.[17]

If the mother is a carrier, and therefore one of her two X chromosomes has a DMD mutation, a 50% chance exists that a female child will inherit that mutation as one of her two X chromosomes, and be a carrier. If that carrier has a male child, there is a 50% chance that he will inherit the X chromosome with the mutation, and will have DMD. Prenatal tests can tell whether the unborn child has the most common mutations. Many mutations are responsible for DMD, and some have not been identified, so genetic testing only works when family members with DMD have an identified mutation.[աղբիւրի կարիք ունի]

Prior to invasive testing, determination of the fetal sex is important; while males are sometimes affected by this X-linked disease, female DMD is extremely rare. This can be achieved by ultrasound scan at 16 weeks or more recently by free fetal DNA testing. Chorion villus sampling (CVS) can be done at 11–14 weeks, and has a 1% risk of miscarriage. Amniocentesis can be done after 15 weeks, and has a 0.5% risk of miscarriage. Fetal blood sampling can be done around 18 weeks.[աղբիւրի կարիք ունի] Another option in the case of unclear genetic test results is fetal muscle biopsy.

Treatment[Խմբագրել | Խմբագրել աղբիւրը]

Salbutamol (albuterol) — a β2 agonist

No cure for DMD is known, and an ongoing medical need has been recognized by regulatory authorities.[18]

Treatment is generally aimed at controlling the onset of symptoms to maximize the quality of life which can be measured using specific questionnaires,[19] and include:

  • Corticosteroids such as prednisolone and deflazacort lead to short-term improvements in muscle strength and function up to 2 years.[20] Corticosteroids have also been reported to help prolong walking, though the evidence for this is not robust.[21]
  • Randomised control trials have shown that β2 agonists increase muscle strength, but do not modify disease progression. Follow-up time for most RCTs on β2 agonists is only around 12 months, hence results cannot be extrapolated beyond that time frame. [աղբիւրի կարիք ունի]
  • Mild, nonjarring physical activity such as swimming is encouraged. Inactivity (such as bed rest) can worsen the muscle disease.
  • Physical therapy is helpful to maintain muscle strength, flexibility, and function.
  • Orthopedic appliances (such as braces and wheelchairs) may improve mobility and the ability for self-care. Form-fitting removable leg braces that hold the ankle in place during sleep can defer the onset of contractures.
  • Appropriate respiratory support as the disease progresses is important.
  • Cardiac problems may require a pacemaker.[22]

The medication eteplirsen has been approved in the United States for the treatment of mutations amenable to dystrophin exon 51 skipping. The US approval has been controversial[23] as eteplirsen failed to establish a clinical benefit;[24] it has been refused approval by the European Medicines Agency.[25]

The medication ataluren have been approved for certain cases in the European Union.[26]

Comprehensive multidisciplinary care guidelines for DMD have been developed by the Centers for Disease Control and Prevention, and were published in two parts in The Lancet Neurology in 2010.[13]

Physical therapy[Խմբագրել | Խմբագրել աղբիւրը]

Հիմնական յօդուած՝ Physical therapy for Duchenne muscular dystrophy։

Physical therapists are concerned with enabling patients to reach their maximum physical potential. Their aim is to:

  • minimize the development of contractures and deformity by developing a programme of stretches and exercises where appropriate
  • anticipate and minimize other secondary complications of a physical nature by recommending bracing and durable medical equipment
  • monitor respiratory function and advise on techniques to assist with breathing exercises and methods of clearing secretions

Respiration assistance[Խմբագրել | Խմբագրել աղբիւրը]

Tracheotomy

Modern "volume ventilators/respirators," which deliver an adjustable volume (amount) of air to the person with each breath, are valuable in the treatment of people with muscular dystrophy-related respiratory problems. The ventilator may require an invasive endotracheal or tracheotomy tube through which air is directly delivered, but for some people, noninvasive delivery through a face mask or mouthpiece is sufficient. Positive airway pressure machines, particularly bilevel ones, are sometimes used in this latter way. The respiratory equipment may easily fit on a ventilator tray on the bottom or back of a power wheelchair with an external battery for portability.

Ventilator treatment may start in the mid- to late teens when the respiratory muscles can begin to collapse. If the vital capacity has dropped below 40% of normal, a volume ventilator/respirator may be used during sleeping hours, a time when the person is most likely to be underventilating (hypoventilating). Hypoventilation during sleep is determined by a thorough history of sleep disorder with an oximetry study and a capillary blood gas (see pulmonary function testing).

A cough assist device can help with excess mucus in lungs by hyperinflation of the lungs with positive air pressure, then negative pressure to get the mucus up. If the vital capacity continues to decline to less than 30 percent of normal, a volume ventilator/respirator may also be needed during the day for more assistance. The person gradually will increase the amount of time using the ventilator/respirator during the day as needed. However, there are also people with the disease in their 20s who have no need for a ventilator.[աղբիւրի կարիք ունի]

Prognosis[Խմբագրել | Խմբագրել աղբիւրը]

Duchenne muscular dystrophy is a rare progressive disease which eventually affects all voluntary muscles and involves the heart and breathing muscles in later stages. Life expectancy is estimated to be around 25-26,[7][3] but this varies. With excellent medical care males are often living into their 30s.[27]

The most common direct cause of death in people with DMD is respiratory failure. Complications from treatment, such as mechanical ventilation and tracheotomy procedures, are also a concern. The next leading cause of death is cardiac-related conditions such as heart failure brought on by dilated cardiomyopathy. With respiratory assistance, the median survival age can reach up to 40. In rare cases, people with DMD have been seen to survive into their forties or early fifties, with proper positioning in wheelchairs and beds, and the use of ventilator support (via tracheostomy or mouthpiece), airway clearance, and heart medications.[28] Early planning of the required supports for later-life care has shown greater longevity for people with DMD.[29]

Curiously, in the mdx mouse model of Duchenne muscular dystrophy, the lack of dystrophin is associated with increased calcium levels and skeletal muscle myonecrosis. The intrinsic laryngeal muscles (ILMs) are protected and do not undergo myonecrosis.[30] ILMs have a calcium regulation system profile suggestive of a better ability to handle calcium changes in comparison to other muscles, and this may provide a mechanistic insight for their unique pathophysiological properties.[31] The ILM may facilitate the development of novel strategies for the prevention and treatment of muscle wasting in a variety of clinical scenarios.[32]

Epidemiology[Խմբագրել | Խմբագրել աղբիւրը]

DMD is the most common type of muscular dystrophy; it affects about one in 5,000 males at birth.[1]

In the US, a 2010 study showed a higher amount of those with DMB age ranging from five to fifty four who are Hispanic compared to Non-Hispanic Whites, and Non-Hispanic Blacks.[33]

History[Խմբագրել | Խմբագրել աղբիւրը]

Dr Guillaume Duchenne de Boulogne

The disease was first described by the Neapolitan physician Giovanni Semmola in 1834 and Gaetano Conte in 1836.[34][35][36] However, DMD is named after the French neurologist Guillaume-Benjamin-Amand Duchenne (1806–1875), who in the 1861 edition of his book Paraplegie hypertrophique de l'enfance de cause cerebrale, described and detailed the case of a boy who had this condition. A year later, he presented photos of his patient in his Album de photographies pathologiques. In 1868, he gave an account of 13 other affected children. Duchenne was the first to do a biopsy to obtain tissue from a living patient for microscopic examination.[37][38]

Notable cases[Խմբագրել | Խմբագրել աղբիւրը]

Alfredo ("Dino", "Alfredino") Ferrari (born January 1932 in Modena), the son of Enzo Ferrari, designed the 1.5 L DOHC V6 engine for the model F2 at the end of 1955. But Dino never saw the engine produced: he died on 30 June 1956 in Modena at the age of 24, before his namesakes Dino and Fiat Dino were made.

Rapper Darius Weems had the disease and used his notoriety to raise awareness and funds for treatment.[39] He died at the age of 27 (his brother also suffered from the disease, until his death at the age of 19). The film Darius Goes West documents Weems's journey of growth and acceptance of having the disease.

Jonathan Evison's novel, The Revised Fundamentals of Caregiving, published in 2012, depicted a young man afflicted by the disease. In 2016, Netflix released The Fundamentals of Caring, a film based on the novel.[աղբիւրի կարիք ունի]

Research[Խմբագրել | Խմբագրել աղբիւրը]

Կաղապար:Outdated section Current research includes exon-skipping, stem cell replacement therapy, analog up-regulation, gene replacement, and supportive care to slow disease progression.[աղբիւրի կարիք ունի]

Efforts are ongoing to find medications the either return the ability to make dystrophin or utrophin.[40] Other efforts include trying to block the entry of calcium ions into muscle cells.[41]

Exon-skipping[Խմբագրել | Խմբագրել աղբիւրը]

Antisense oligonucleotides (oligos), structural analogs of DNA, are the basis of a potential treatment for 10% of people with DMD.[42] The compounds allow faulty parts of the dystrophin gene to be skipped when it is transcribed to RNA for protein production, permitting a still-truncated but more functional version of the protein to be produced.[43] It is also known as nonsense suppression therapy.[44]

Two kinds of antisense oligos, 2'-O-methyl phosphorothioate oligos (like drisapersen) and Morpholino oligos (like eteplirsen), have tentative evidence of benefit and are being studied.[45] Eteplirsen is targeted to skip exon 51. "As an example, skipping exon 51 restores the reading frame of ~ 15% of all the boys with deletions. It has been suggested that by having 10 AONs to skip 10 different exons it would be possible to deal with more than 70% of all DMD boys with deletions."[42] This represents about 1.5% of cases.[42]

Reading Frame

People with Becker's muscular dystrophy, which is milder than DMD, have a form of dystrophin which is functional even though it is shorter than normal dystrophin.[46] In 1990 England et al. noticed that a patient with mild Becker muscular dystrophy was lacking 46% of his coding region for dystrophin.[46] This functional, yet truncated, form of dystrophin gave rise to the notion that shorter dystrophin can still be therapeutically beneficial. Concurrently, Kole et al. had modified splicing by targeting pre-mRNA with antisense oligonucleotides (AONs).[47] Kole demonstrated success using splice-targeted AONs to correct missplicing in cells removed from beta-thalassemia patients[48][49] Wilton's group tested exon skipping for muscular dystrophy.[50][51]

Gene therapy[Խմբագրել | Խմբագրել աղբիւրը]

CRISPR overview

Researchers are working on a gene editing method to correct a mutation that leads to Duchenne muscular dystrophy (DMD).[52] Researchers used a technique called CRISPR/Cas9-mediated genome editing, which can precisely remove a mutation in the dystrophin gene in DNA, allowing the body’s DNA repair mechanisms to replace it with a normal copy of the gene.[53][54] The benefit of this over other gene therapy techniques is that it can permanently correct the “defect” in a gene rather than just transiently adding a “functional” one.

Genome editing through the CRISPR/Cas9 system is not currently feasible in humans. However, it may be possible, through advancements in technology, to use this technique to develop therapies for DMD in the future.[55][56] In 2007, researchers did the world's first clinical (viral-mediated) gene therapy trial for Duchenne MD.[57]

Biostrophin is a delivery vector for gene therapy in the treatment of Duchenne muscular dystrophy and Becker muscular dystrophy.[58]

References[Խմբագրել | Խմբագրել աղբիւրը]

  1. ↑ 1,00 1,01 1,02 1,03 1,04 1,05 1,06 1,07 1,08 1,09 1,10 1,11 1,12 1,13 1,14 1,15 1,16 1,17 1,18 «Muscular Dystrophy: Hope Through Research»։ NINDS։ March 4, 2016։ արխիւացուած է բնօրինակէն-էն՝ 30 September 2016-ին։ արտագրուած է՝ 12 September 2016 
  2. ↑ 2,0 2,1 2,2 2,3 «NINDS Muscular Dystrophy Information Page»։ NINDS։ March 4, 2016։ արխիւացուած է բնօրինակէն-էն՝ 30 July 2016-ին։ արտագրուած է՝ 12 September 2016 
  3. ↑ 3,0 3,1 Lisak RP, Truong DD, Carroll W, Bhidayasiri R (2011)։ International Neurology։ Wiley։ էջ 222։ ISBN 9781444317015 
  4. ↑ Rowland L.P. (1985)։ «Clinical Perspective: Phenotypic Expression In Muscular Dystrophy»։ in Strohman C., Wolf S.։ Gene Expression in Muscle։ Plenum Press։ էջեր 3–5։ ISBN 978-1-4684-4907-5 
  5. ↑ Կաղապար:OMIM
  6. ↑ «Duchenne Muscular Dystrophy: Pathophysiological Implications of Mitochondrial Calcium Signaling and ROS Production»։ 2012-05-02։ արխիւացուած է բնօրինակէն-էն՝ May 2, 2012-ին։ արտագրուած է՝ 2014-06-29 
  7. ↑ 7,0 7,1 7,2 Մէջբերման սխալ՝ Invalid <ref> tag; no text was provided for refs named MedlinePlusEncyclopedia000705
  8. ↑ Մէջբերման սխալ՝ Invalid <ref> tag; no text was provided for refs named Noz2016
  9. ↑ Wahl Margaret (October 21, 2016)։ «Quest - Article - But Girls Don't Get Duchenne, or Do They? - A Quest Article»։ Muscular Dystrophy Association։ արտագրուած է՝ July 6, 2019 
  10. ↑ «Understanding Genetics» 
  11. ↑ «Morphofunctional aspects of the blood-brain barrier»։ Current Drug Metabolism 13 (1): 50–60։ January 2012։ PMID 22292807։ doi:10.2174/138920012798356970 
  12. ↑ «University of Utah Muscular Dystrophy»։ Genome.utah.edu։ 2009-11-28։ արտագրուած է՝ 2013-02-16 
  13. ↑ 13,0 13,1 «Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management»։ The Lancet. Neurology 9 (1): 77–93։ January 2010։ PMID 19945913։ doi:10.1016/s1474-4422(09)70271-6 
  14. ↑ «Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 2. Correlations within individual patients»։ Journal of Medical Genetics 30 (9): 737–44։ September 1993։ PMC 1016530։ PMID 8411068։ doi:10.1136/jmg.30.9.737 
  15. ↑ «Is a muscle biopsy in Duchenne dystrophy really necessary?»։ Neurology 57 (4): 574–5։ August 2001։ PMID 11524463։ doi:10.1212/wnl.57.4.574 
  16. ↑ «Rapid direct sequence analysis of the dystrophin gene»։ American Journal of Human Genetics 72 (4): 931–9։ April 2003։ PMC 1180355։ PMID 12632325։ doi:10.1086/374176 
  17. ↑ «Duchenne and Becker muscular dystrophy, National Institutes of health»։ Ghr.nlm.nih.gov։ 2013-02-11։ արխիւացուած է բնօրինակէն-էն՝ 2013-02-07-ին։ արտագրուած է՝ 2013-02-16 
  18. ↑ «Duchenne Muscular Dystrophy Statement»։ Drug Safety and Availability։ US FDA։ 2014-10-31։ արխիւացուած է բնօրինակէն-էն՝ 2014-11-02-ին 
  19. ↑ «Construction of a Quality of Life Questionnaire for slowly progressive neuromuscular disease»։ Quality of Life Research 24 (11): 2615–23։ November 2015։ PMID 26141500։ doi:10.1007/s11136-015-1013-8 
  20. ↑ «Duchenne Muscular Dystrophy: From Diagnosis to Therapy»։ Molecules 20 (10): 18168–84։ October 2015։ PMC 6332113 ։ PMID 26457695։ doi:10.3390/molecules201018168 
  21. ↑ «Corticosteroids for the treatment of Duchenne muscular dystrophy»։ The Cochrane Database of Systematic Reviews 5 (5): CD003725։ May 2016։ PMID 27149418։ doi:10.1002/14651858.CD003725.pub4 
  22. ↑ «Cardiac involvement in patients with muscular dystrophies: magnetic resonance imaging phenotype and genotypic considerations»։ Circulation: Cardiovascular Imaging 4 (1): 67–76։ January 2011։ PMC 3057042։ PMID 21245364։ doi:10.1161/CIRCIMAGING.110.960740 
  23. ↑ «Railroading at the FDA»։ Nature Biotechnology (անգլերեն) 34 (11): 1078։ 2016-11-08։ PMID 27824847։ doi:10.1038/nbt.3733 
  24. ↑ «FDAetep» (անգլերեն)։ 19 September 2016։ արտագրուած է՝ 8 July 2019 
  25. ↑ «CHMP Advises Against Approval for Eteplirsen in DMD»։ Medscape։ արտագրուած է՝ 2019-07-09 
  26. ↑ «Translarna - Summary of Product Characteristics» (անգլերեն)։ UK Electronic Medicines Compendium։ 24 April 2017։ արտագրուած է՝ 18 June 2017 
  27. ↑ «Duchenne muscular dystrophy (DMD) | Muscular Dystrophy Campaign»։ Muscular-dystrophy.org։ արխիւացուած է բնօրինակէն-էն՝ 2013-01-21-ին։ արտագրուած է՝ 2013-02-16 
  28. ↑ «Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011»։ Annals of Physical and Rehabilitation Medicine 56 (6): 443–54։ September 2013։ PMID 23876223։ doi:10.1016/j.rehab.2013.06.002 
  29. ↑ «[Personal experimental experience with the administration of liquid obliterative agents using percutaneous intra-arterial balloon catheters with a controlled leak]»։ Sbornik Vedeckych Praci Lekarske Fakulty Karlovy Univerzity V Hradci Kralove. Supplementum 30 (2): 201–11։ 2012-11-22։ PMC 3504593։ PMID 3504593։ doi:10.1186/1750-1172-7-S2-A8 
  30. ↑ «Intrinsic laryngeal muscles are spared from myonecrosis in the mdx mouse model of Duchenne muscular dystrophy»։ Muscle & Nerve 35 (3): 349–53։ March 2007։ PMID 17143878։ doi:10.1002/mus.20697 
  31. ↑ «Expression of calcium-buffering proteins in rat intrinsic laryngeal muscles»։ Physiological Reports 3 (6): e12409։ June 2015։ PMC 4510619։ PMID 26109185։ doi:10.14814/phy2.12409 
  32. ↑ «Intrinsic Laryngeal Muscles and Potential Treatments for Skeletal Muscle-Wasting Disorders»։ Austin Journal of Otolaryngology 1 (1): 3։ 2014։ արխիւացուած է բնօրինակէն-էն՝ 2015-06-26-ին 
  33. ↑ «Key Findings: Prevalence of Duchenne / Becker Muscular Dystrophies»։ Centers for Disease Control and Prevention (en-us)։ 2018-01-05։ արտագրուած է՝ 2018-11-18 
  34. ↑ Politano L։ «Cardiomiologia e Genetica Medica» [Cardiomyology and Medical Genetics] (Italian)։ Seconda Università degli Studi di Napoli։ արխիւացուած է բնօրինակէն-էն՝ July 4, 2015-ին։ արտագրուած է՝ August 24, 2015 
  35. ↑ De Rosa G (October 2005)։ «Da Conte a Duchenne» [By Conte in Duchenne]։ DM (Italian)։ Unione Italiana Lotta alla Distrofia Muscolare։ արխիւացուած է բնօրինակէն-էն՝ March 4, 2016-ին։ արտագրուած է՝ August 24, 2015 
  36. ↑ «One-hundred-seventy-five years of Neapolitan contributions to the fight against the muscular diseases»։ Acta Myologica 29 (3): 369–91։ December 2010։ PMC 3146338։ PMID 21574522 
  37. ↑ «Duchenne muscular dystrophy»։ Medterms.com։ 2011-04-27։ արխիւացուած է բնօրինակէն-էն՝ 2012-08-06-ին։ արտագրուած է՝ 2013-02-16 
  38. ↑ Կաղապար:WhoNamedIt
  39. ↑ McFadden C (November 22, 2012)։ «Darius Weems' Next Chapter: Rap Star With Duchenne Muscular Dystrophy Tries Clinical Trial»։ արխիւացուած է բնօրինակէն-էն՝ August 5, 2016-ին։ արտագրուած է՝ June 29, 2016 
  40. ↑ «Pharmacological advances for treatment in Duchenne muscular dystrophy»։ Current Opinion in Pharmacology 34: 36–48։ June 2017։ PMID 28486179։ doi:10.1016/j.coph.2017.04.002 
  41. ↑ «Calcium and the damage pathways in muscular dystrophy»։ Canadian Journal of Physiology and Pharmacology 88 (2): 83–91։ February 2010։ PMID 20237582։ doi:10.1139/Y09-058 
  42. ↑ 42,0 42,1 42,2 «Genetic therapies for inherited neuromuscular disorders»։ The Lancet. Child & Adolescent Health 2 (8): 600–609։ August 2018։ PMID 30119719 ։ doi:10.1016/S2352-4642(18)30140-8 
  43. ↑ «Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides»։ Human Molecular Genetics 7 (7): 1083–90։ July 1998։ PMID 9618164։ doi:10.1093/hmg/7.7.1083 
  44. ↑ «Read-through strategies for suppression of nonsense mutations in Duchenne/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124)»։ Journal of Child Neurology 25 (9): 1158–64։ September 2010։ PMC 3674569։ PMID 20519671։ doi:10.1177/0883073810371129 
  45. ↑ «FDA grants accelerated approval to first drug for Duchenne muscular dystrophy» (Press release)։ FDA։ September 19, 2016։ արխիւացուած է բնօրինակէն-էն՝ December 11, 2016-ին։ արտագրուած է՝ 2016-12-12 
  46. ↑ 46,0 46,1 «Very mild muscular dystrophy associated with the deletion of 46% of dystrophin»։ Nature 343 (6254): 180–2։ January 1990։ Bibcode:1990Natur.343..180E։ PMID 2404210։ doi:10.1038/343180a0 
  47. ↑ «Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides»։ Proceedings of the National Academy of Sciences of the United States of America 90 (18): 8673–7։ September 1993։ Bibcode:1993PNAS...90.8673D։ PMC 47420։ PMID 8378346։ doi:10.1073/pnas.90.18.8673 
  48. ↑ «Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients»։ Proceedings of the National Academy of Sciences of the United States of America 97 (17): 9591–6։ August 2000։ Bibcode:2000PNAS...97.9591L։ PMC 16909։ PMID 10944225։ doi:10.1073/pnas.97.17.9591 
  49. ↑ «Restoration of human beta-globin gene expression in murine and human IVS2-654 thalassemic erythroid cells by free uptake of antisense oligonucleotides»։ Molecular Pharmacology 62 (3): 545–53։ September 2002։ PMID 12181431։ doi:10.1124/mol.62.3.545 
  50. ↑ «Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides»։ Neuromuscular Disorders 9 (5): 330–8։ July 1999։ PMID 10407856։ doi:10.1016/S0960-8966(99)00010-3 
  51. ↑ «Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript»։ Molecular Therapy 15 (7): 1288–96։ July 2007։ PMID 17285139։ doi:10.1038/sj.mt.6300095 
  52. ↑ «Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing»։ Science Advances 4 (1): eaap9004։ January 2018։ Bibcode:2018SciA....4P9004L։ PMC 5796795 ։ PMID 29404407։ doi:10.1126/sciadv.aap9004 
  53. ↑ Cohen J (2018-08-30)։ «Gene editing of dogs offers hope for treating human muscular dystrophy»։ Science։ doi:10.1126/science.aav2676 
  54. ↑ Patmanathan Sathya Narayanan, Gnanasegaran Nareshwaran, Lim Moon Nian, Husaini Roslina, Fakiruddin Kamal Shaik, Zakaria Zubaidah (2018)։ «CRISPR/Cas9 in Stem Cell Research: Current Application and Future Perspective»։ Current Stem Cell Research & Therapy 13 (8): 632–644։ PMID 29895256։ doi:10.2174/1574888X13666180613081443 
  55. ↑ «Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA»։ Science 345 (6201): 1184–1188։ September 2014։ Bibcode:2014Sci...345.1184L։ PMC 4398027։ PMID 25123483։ doi:10.1126/science.1254445 
  56. ↑ Wade N (31 December 2015)։ «Gene Editing Offers Hope for Treating Duchenne Muscular Dystrophy, Studies Find»։ The New York Times։ արխիւացուած է բնօրինակէն-էն՝ 2 January 2016-ին։ արտագրուած է՝ 1 January 2016 
  57. ↑ «Gene therapy for duchenne muscular dystrophy: expectations and challenges»։ Archives of Neurology 64 (9): 1236–41։ September 2007։ PMID 17846262։ doi:10.1001/archneur.64.9.1236 
  58. ↑ «Chronicles in drug discovery»։ Drug News & Perspectives 18 (8): 517–22։ October 2005։ PMID 16391721։ doi:10.1358/dnp.2005.18.8.953409 
Վերցուած է «https://hyw.wikipedia.org/w/index.php?title=Մասնակից:Giragos16/Սեւագրութիւն&oldid=167281» էջէն